Caspofungin
- Generic Name
- Caspofungin
- Brand Names
- Cancidas, Cancidas (previously Caspofungin MSD)
- Drug Type
- Small Molecule
- Chemical Formula
- C52H88N10O15
- CAS Number
- 162808-62-0
- Unique Ingredient Identifier
- F0XDI6ZL63
- Background
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
- Indication
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
- Associated Conditions
- Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections
Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Mycoses Study Group
- Target Recruit Count
- 222
- Registration Number
- NCT00520234
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Prophylaxis of Fungal Invasive Infections in Leukemia
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2009-09-22
- Lead Sponsor
- Northern Italy Leukemia Group
- Target Recruit Count
- 100
- Registration Number
- NCT00501098
- Locations
- 🇮🇹
USC Ematologia Ospedali Riuniti di Bergamo, Bergamo, BG, Italy
🇮🇹Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
🇮🇹Ematologia Centro TMO - Fondazione IRCSS Ospedale Maggiore, Milano, MI, Italy
Antimicrobial PK in Infants With Suspected or Confirmed Infection
- Conditions
- Infection
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Duke University
- Target Recruit Count
- 450
- Registration Number
- NCT00491426
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of California at San Diego, La Jolla, California, United States
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
- Conditions
- MycosesCandidiasis, InvasiveCandidemia
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 450
- Registration Number
- NCT00413218
- Locations
- 🇺🇸
Idaho Falls Infectious Diseases PLLC, Idaho Falls, Idaho, United States
🇺🇸Somero Research Corporation, Palm Desert, California, United States
🇺🇸Loyola University Hospital, Maywood, Illinois, United States
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 46
- Registration Number
- NCT00404092
- Locations
- 🇧🇪
University Hospital Gasthuisberg, Leuven, Belgium
🇩🇪Klinikum der Universität zu Köln, Köln, Germany
🇩🇪Charité - Campus Benjamin Franklin, Berlin, Germany
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2009-05-13
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 320
- Registration Number
- NCT00388167
- Locations
- 🇪🇸
Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Xarxa assistencial de Manresa, Manresa, Barcelona, Spain
A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)
- Conditions
- Fungal Infection
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00379964
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
- Conditions
- Invasive Aspergillosis
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00334412
- Locations
- 🇫🇷
Gilead Sciences, Paris, France
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
- Conditions
- Liver TransplantationFungal Infection
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2007-04-13
- Lead Sponsor
- Grupo de Estudio de Infecciones en Transplantados
- Target Recruit Count
- 70
- Registration Number
- NCT00333645
- Locations
- 🇪🇸
Hospital Ramon y Cajal, Madrid, Spain
🇪🇸Hospital Universitario La Fe, Valencia, Spain
🇪🇸Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)
- Conditions
- Candidiasis
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00330395
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.